global development and commercialization

UPPSALA: Oasmia Pharmaceutical AB has signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer. The agreement is the…